ROSA MARÍA
AYALA DÍAZ
Profesora asociada de Ciencias de la Salud
Hospital Universitario 12 de Octubre
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (82)
2023
-
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681
-
Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
Life, Vol. 13, Núm. 9
-
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma (Journal of Hematology & Oncology, (2023), 16, 1, (76), 10.1186/s13045-023-01474-w)
Journal of Hematology and Oncology
-
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
Frontiers in immunology
-
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients (Frontiers in Immunology, (2023), 14, (1188818), 10.3389/fimmu.2023.1188818)
Frontiers in Immunology
-
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
Journal of Hematology and Oncology
-
Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE
Frontiers in Pharmacology, Vol. 14
-
Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT
Leukemia, Vol. 37, Núm. 3, pp. 659-669
-
Should we move to a genomic classification of neutrophilic myeloid neoplasms?
Blood Advances
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports, Vol. 12, Núm. 1
-
Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: An age-matched cohorts study
Clinical Infection in Practice, Vol. 13
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
-
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group
Disease markers, Vol. 2022, pp. 3132941
-
Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network
Blood Cancer Journal, Vol. 12, Núm. 6
-
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538
-
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols
British Journal of Haematology, Vol. 196, Núm. 3, pp. 670-675
-
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Cancer, Vol. 128, Núm. 13, pp. 2441-2448
-
The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies
Cancers, Vol. 14, Núm. 5